What Happened?

Shares of clinical research company IQVIA (NYSE: IQV) jumped 3.6% in the afternoon session after Bank of America raised its price target on the company's shares to $230 from $215. The adjustment from the investment bank suggested a more positive outlook on the stock's potential value. This move occurred while the company maintained an average rating of 'buy' among analysts polled by FactSet. An increased price target can signal confidence in a company's future performance, which often attracts investor interest.

After the initial pop the shares cooled down to $211.89, up 3.6% from previous close.

Is now the time to buy IQVIA? Access our full analysis report here.

What Is The Market Telling Us

IQVIA’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 19 days ago when the stock gained 6.3% on the news that the company, in partnership with GSK, announced a major update to its Vaccine Track data tool for tracking adult immunization activity in the U.S. The enhancement adds local-level data for 387 metro areas and expands the dataset to a full decade of information. This update is designed to help public health organizations and providers identify immunization gaps and improve their community outreach efforts. The collaboration with pharmaceutical giant GSK underscores IQVIA's role in providing critical health data analytics. This development occurs within a positive industry context, as the broader biologics contract research organization market, a key sector for IQVIA, is projected to experience strong growth due to increased outsourcing of R&D by large pharmaceutical firms.

IQVIA is up 8.6% since the beginning of the year, and at $211.89 per share, it is trading close to its 52-week high of $231.19 from October 2024. Investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at an investment worth $1,221.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.